Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Curr Opin Hematol ; 28(5): 315-322, 2021 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-34397591

RESUMEN

PURPOSE OF REVIEW: To summarize the recent literature related to female hemophilia A carriers with respect to prevalence in the population, the impact of baseline factor VIII levels and other influences on bleeding phenotype, and clinical management needs. RECENT FINDINGS: Many female hemophilia A carriers are at risk for abnormal bleeding, yet they are underrecognized by healthcare providers and their bleeding symptoms are underreported. Low FVIII levels are consistently associated with clinically significant bleeding and correlate well with skewed X chromosome inactivation (XCI). Most interestingly, bleeding tendency is also observed in some hemophilia A carriers with normal factor VIII levels and requires further investigation. Well controlled studies investigating peripartum and periprocedural FVIII levels and adequate hemostatic treatment are necessary to inform management guidelines. SUMMARY: Prevalence and bleeding tendency of hemophilia A carriers remain underreported, despite a significant proportion having low FVIII levels. Skewed XCI may explain low FVIII but does not explain the bleeding risk encountered in a larger proportion of hemophilia A carriers with random XCI and borderline/normal FVIII.


Asunto(s)
Cromosomas Humanos X/genética , Factor VIII , Hemofilia A , Hemorragia , Heterocigoto , Fenotipo , Factor VIII/genética , Factor VIII/metabolismo , Femenino , Hemofilia A/sangre , Hemofilia A/genética , Hemorragia/sangre , Hemorragia/genética , Humanos
2.
Oncology (Williston Park) ; 27(2): 126-30, 132-6, 138, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23530404

RESUMEN

Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) is a disease of the elderly, but our current guidelines and treatment paradigms for this disease are based on studies that have mainly enrolled younger patients. Because the number of people living beyond the age of 80 increased by more than 250% between 1960 and 2000, and since it is expected that the population over the age of 75 will triple by 2030, understanding how these elderly patients should be treated is paramount to improving outcomes for this potentially curable lymphoma. In this review, we outline the scope of the problem; we define "the elderly" and identify challenges in assessing this patient population. We also summarize pivotal studies that have been conducted in these elderly patients and suggest an algorithm to aid clinicians in making treatment decisions when faced with DLBCL patients older than 80.


Asunto(s)
Evaluación Geriátrica , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Anticuerpos Monoclonales de Origen Murino/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Neoplasias Encefálicas/prevención & control , Comorbilidad , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Humanos , Prednisona/administración & dosificación , Recurrencia , Rituximab , Vincristina/administración & dosificación
3.
Obstet Gynecol ; 142(2): 251-256, 2023 08 01.
Artículo en Inglés | MEDLINE | ID: mdl-37411028

RESUMEN

Approximately 2% of the general population have an underlying inherited bleeding disorder, which, for adolescents and young adult women, has both physical risks and adverse psychosocial effects. Heavy menstrual bleeding can be the first sign of an underlying bleeding disorder such as von Willebrand disease and the X-linked bleeding disorders hemophilia A and B. Connective tissue disorders such as Ehlers-Danlos syndrome, in particular the hypermobile subtype, are relatively frequent in the general population and can also cause bleeding symptoms from impaired hemostasis due to defective collagen. For more than 20 years, the American College of Obstetricians and Gynecologists (ACOG) has recommended screening adolescents and young adult women for bleeding disorders when they present with heavy menstrual bleeding. Despite this directive, there is a significant gap from symptom onset to time of diagnosis in this patient population. We must work to effectively close this diagnostic gap by consistently obtaining thorough bleeding histories, performing the appropriate laboratory evaluations, working collaboratively with hematologists, and using tools and materials promoted by ACOG. Improved screening and earlier diagnosis of these individuals can have far-reaching effects that are not limited to heavy menstrual bleeding management and extend to peripartum considerations and prenatal counseling.


Asunto(s)
Menorragia , Enfermedades de von Willebrand , Embarazo , Humanos , Femenino , Adolescente , Adulto Joven , Menorragia/diagnóstico , Menorragia/etiología , Hemorragia/etiología , Enfermedades de von Willebrand/diagnóstico , Enfermedades de von Willebrand/complicaciones , Bases de Datos Genéticas , Laboratorios
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA